for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover The Lancet
   Journal TOC RSS feeds Export to Zotero [1082 followers]  Follow    
   Full-text available via subscription Subscription journal
     ISSN (Print) 0140-6736 - ISSN (Online) 1474-547X
     Published by Elsevier Homepage  [2563 journals]   [SJR: 7.074]   [H-I: 477]
  • A bioresorbable everolimus-eluting scaffold versus a metallic
           everolimus-eluting stent for ischaemic heart disease caused by de-novo
           native coronary artery lesions (ABSORB II): an interim 1-year analysis of
           clinical and procedural secondary outcomes from a randomised controlled
           trial
    • Abstract: Publication date: Available online 14 September 2014
      Source:The Lancet
      Author(s): Patrick W Serruys , Bernard Chevalier , Dariusz Dudek , Angel Cequier , Didier Carrié , Andres Iniguez , Marcello Dominici , René J van der Schaaf , Michael Haude , Luc Wasungu , Susan Veldhof , Lei Peng , Peter Staehr , Maik J Grundeken , Yuki Ishibashi , Hector M Garcia-Garcia , Yoshinobu Onuma
      Background Despite rapid dissemination of an everolimus-eluting bioresorbable scaffold for treatment for coronary artery disease, no data from comparisons with its metallic stent counterpart are available. In a randomised controlled trial we aimed to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent. Here we report secondary clinical and procedural outcomes after 1 year of follow-up. Methods In a single-blind, multicentre, randomised trial, we enrolled eligible patients aged 18–85 years with evidence of myocardial ischaemia and one or two de-novo native lesions in different epicardial vessels. We randomly assigned patients in a 2:1 ratio to receive treatment with an everolimus-eluting bioresorbable scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) or treatment with an everolimus-eluting metallic stent (Xience, Abbott Vascular, Santa Clara, CA, USA). Randomisation was stratified by diabetes status and number of planned target lesions. The co-primary endpoints of this study are vasomotion (change in mean lumen diameter before and after nitrate administration at 3 years) and difference between minimum lumen diameter (after nitrate administration) after the index procedure and at 3 years. Secondary endpoints were procedural performance assessed by quantitative angiography and intravascular ultrasound; composite clinical endpoints based on death, myocardial infarction, and coronary revascularisation; device and procedural success; and angina status assessed by the Seattle Angina Questionnaire and exercise testing at 6 and 12 months. Cumulative angina rate based on adverse event reporting was analysed post hoc. This trial is registered at ClinicalTrials.gov, number NCT01425281. Findings Between Nov 28, 2011, and June 4, 2013, we enrolled 501 patients and randomly assigned them to the bioresorbable scaffold group (335 patients, 364 lesions) or the metallic stent group (166 patients, 182 lesions). Dilatation pressure and balloon diameter at the highest pressure during implantation or postdilatation were higher and larger in the metallic stent group, whereas the acute recoil post implantation was similar (0·19 mm for both, p=0·85). Acute lumen gain was lower for the bioresorbable scaffold by quantitative coronary angiography (1·15 mm vs 1·46 mm, p<0·0001) and quantitative intravascular ultrasound (2·85 mm2 vs 3·60 mm2, p<0·0001), resulting in a smaller lumen diameter or area post procedure. At 1 year, however, cumulative rates of first new or worsening angina from adverse event reporting were lower (72 patients [22%] in the bioresorbable scaffold group vs 50 [30%] in the metallic stent group, p=0·04), whereas performance during maximum exercise and angina status by SAQ were similar. The 1-year composite device orientated endpoint was similar between the bioresorbable scaffold and metallic stent groups (16 patients [5%] vs five patients [3%], p=0·35). Three patients in the bioresorbable scaffold group had definite or probable scaffold thromboses (one definite acute, one definite sub-acute, and one probable late), compared with no patients in the metallic stent group. There were 17 (5%) major cardiac adverse events in the bioresorbable scaffold group compared with five (3%) events in the metallic stent group, with the most common adverse events being myocardial infarction (15 cases [4%] vs two cases [1%], respectively) and clinically indicated target-lesion revascularisation (four cases [1%] vs three cases [2%], respectively). Interpretation The everolimus-eluting bioresorbable scaffold showed similar 1-year composite secondary clinical outcomes to the everolimus-eluting metallic stent.
      PubDate: 2014-09-17T15:46:30Z
       
  • Biodegradable stents: the golden future of angioplasty?
    • Abstract: Publication date: Available online 14 September 2014
      Source:The Lancet
      Author(s): Carlo Di Mario , Gianluca Caiazzo



      PubDate: 2014-09-17T15:46:30Z
       
  • Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a
           phase 3 randomised controlled trial
    • Abstract: Publication date: Available online 14 September 2014
      Source:The Lancet
      Author(s): Ben J Slotman , Harm van Tinteren , John O Praag , Joost L Knegjens , Sherif Y El Sharouni , Matthew Hatton , Astrid Keijser , Suresh Senan , Corinne Faivre-Finn
      Background Most patients with extensive stage small-cell lung cancer (ES-SCLC) who undergo chemotherapy, and prophylactic cranial irradiation, have persistent intrathoracic disease. We assessed thoracic radiotherapy for treatment of this patient group. Methods We did this phase 3 randomised controlled trial at 42 hospitals: 16 in Netherlands, 22 in the UK, three in Norway, and one in Belgium. We enrolled patients with WHO performance score 0–2 and confirmed ES-SCLC who responded to chemotherapy. They were randomly assigned (1:1) to receive either thoracic radiotherapy (30 Gy in ten fractions) or no thoracic radiotherapy. All underwent prophylactic cranial irradiation. The primary endpoint was overall survival at 1 year in the intention-to-treat population. Secondary endpoints included progression-free survival. This study is registered with the Nederlands Trial Register, number NTR1527. Findings We randomly assigned 498 patients between Feb 18, 2009, and Dec 21, 2012. Three withdrew informed consent, leaving 247 patients in the thoracic radiotherapy group and 248 in the control group. Mean interval between diagnosis and randomisation was 17 weeks. Median follow-up was 24 months. Overall survival at 1 year was not significantly different between groups: 33% (95% CI 27–39) for the thoracic radiotherapy group versus 28% (95% CI 22–34) for the control group (hazard ratio [HR] 0·84, 95% CI 0·69–1·01; p=0·066). However, in a secondary analysis, 2-year overall survival was 13% (95% CI 9–19) versus 3% (95% CI 2–8; p=0·004). Progression was less likely in the thoracic radiotherapy group than in the control group (HR 0·73, 95% CI 0·61–0·87; p=0·001). At 6 months, progression-free survival was 24% (95% CI 19–30) versus 7% (95% CI 4–11; p=0·001). We recorded no severe toxic effects. The most common grade 3 or higher toxic effects were fatigue (11 vs 9) and dyspnoea (three vs four). Interpretation Thoracic radiotherapy in addition to prophylactic cranial irradiation should be considered for all patients with ES-SCLC who respond to chemotherapy. Funding Dutch Cancer Society (CKTO), Dutch Lung Cancer Research Group, Cancer Research UK, Manchester Academic Health Science Centre Trials Coordination Unit, and the UK National Cancer Research Network.


      PubDate: 2014-09-17T15:46:30Z
       
  • Neonatal and infant death: the Apgar score reassessed
    • Abstract: Publication date: Available online 15 September 2014
      Source:The Lancet
      Author(s): Abbot R Laptook



      PubDate: 2014-09-17T15:46:30Z
       
  • Richard III: skeletal evidence of perimortem trauma
    • Abstract: Publication date: Available online 16 September 2014
      Source:The Lancet
      Author(s): Heather E Bonney



      PubDate: 2014-09-17T15:46:30Z
       
  • Apgar score and the risk of cause-specific infant mortality: a
           population-based cohort study
    • Abstract: Publication date: Available online 15 September 2014
      Source:The Lancet
      Author(s): Stamatina Iliodromiti , Daniel F Mackay , Gordon C S Smith , Jill P Pell , Scott M Nelson
      Background The Apgar score has been used worldwide as an index of early neonatal condition for more than 60 years. With advances in health-care service provision, neonatal resuscitation, and infant care, its present relevance is unclear. The aim of the study was to establish the strength of the relation between Apgar score at 5 min and the risk of neonatal and infant mortality, subdivided by specific causes. Methods We linked routine discharge and mortality data for all births in Scotland, UK between 1992 and 2010. We restricted our analyses to singleton livebirths, in women aged over 10 years, with a gestational age at delivery between 22 and 44 weeks, and excluded deaths due to congenital anomalies or isoimmunisation. We calculated the relative risks (RRs) of neonatal and infant death of neonates with low (0–3) and intermediate (4–6) Apgar scores at 5 min referent to neonates with normal Apgar score (7–10) using binomial log-linear modelling with adjustment for confounders. Analyses were stratified by gestational age at birth because it was a significant effect modifier. Missing covariate data were imputed. Findings Complete data were available for 1 029 207 eligible livebirths. Across all gestational strata, low Apgar score at 5 min was associated with an increased risk of neonatal and infant death. However, the strength of the association (adjusted RR, 95% CI referent to Apgar 7–10) was strongest at term (p<0·0001). A low Apgar (0–3) was associated with an adjusted RR of 359·4 (95% CI 277·3–465·9) for early neonatal death, 30·5 (18·0–51·6) for late neonatal death, and 50·2 (42·8–59·0) for infant death. We noted similar associations of a lower magnitude for intermediate Apgar (4–6). The strongest associations were for deaths attributed to anoxia and low Apgar (0–3) for term infants (RR 961·7, 95% CI 681·3–1357·5) and preterm infants (141·7, 90·1–222·8). No association between Apgar score at 5 min and the risk of sudden infant death syndrome was noted at any gestational age (RR 0·6, 95% CI 0·1–4·6 at term; 1·2, 0·3–4·8 at preterm). Interpretation Low Apgar score at 5 min was strongly associated with the risk of neonatal and infant death. Our findings support its continued usefulness in contemporary practice. Funding None.


      PubDate: 2014-09-17T15:46:30Z
       
  • Perimortem trauma in King Richard III: a skeletal analysis
    • Abstract: Publication date: Available online 16 September 2014
      Source:The Lancet
      Author(s): Jo Appleby , Guy N Rutty , Sarah V Hainsworth , Robert C Woosnam-Savage , Bruno Morgan , Alison Brough , Richard W Earp , Claire Robinson , Turi E King , Mathew Morris , Richard Buckley
      Background Richard III was the last king of England to die in battle, but how he died is unknown. On Sept 4, 2012, a skeleton was excavated in Leicester that was identified as Richard. We investigated the trauma to the skeleton with modern forensic techniques, such as conventional CT and micro-CT scanning, to characterise the injuries and establish the probable cause of death. Methods We assessed age and sex through direct analysis of the skeleton and from CT images. All bones were examined under direct light and multi-spectral illumination. We then scanned the skeleton with whole-body post-mortem CT. We subsequently examined bones with identified injuries with micro-CT. We deemed that trauma was perimortem when we recorded no evidence of healing and when breakage characteristics were typical of fresh bone. We used previous data to identify the weapons responsible for the recorded injuries. Findings The skeleton was that of an adult man with a gracile build and severe scoliosis of the thoracic spine. Standard anthropological age estimation techniques based on dry bone analysis gave an age range between 20s and 30s. Standard post-mortem CT methods were used to assess rib end morphology, auricular surfaces, pubic symphyseal face, and cranial sutures, to produce a multifactorial narrower age range estimation of 30–34 years. We identified nine perimortem injuries to the skull and two to the postcranial skeleton. We identified no healed injuries. The injuries were consistent with those created by weapons from the later medieval period. We could not identify the specific order of the injuries, because they were all distinct, with no overlapping wounds. Three of the injuries—two to the inferior cranium and one to the pelvis—could have been fatal. Interpretation The wounds to the skull suggest that Richard was not wearing a helmet, although the absence of defensive wounds on his arms and hands suggests he was still otherwise armoured. Therefore, the potentially fatal pelvis injury was probably received post mortem, meaning that the most likely injuries to have caused his death are the two to the inferior cranium. Funding The University of Leicester.


      PubDate: 2014-09-17T15:46:30Z
       
  • Small-cell lung cancer: local therapy for a systemic disease?
    • Abstract: Publication date: Available online 14 September 2014
      Source:The Lancet
      Author(s): Jan P van Meerbeeck , David Ball



      PubDate: 2014-09-17T15:46:30Z
       
  • WHO meeting chooses untried interventions to defeat Ebola
    • Abstract: Publication date: Available online 12 September 2014
      Source:The Lancet
      Author(s): John Maurice



      PubDate: 2014-09-17T15:46:30Z
       
  • Dengue
    • Abstract: Publication date: Available online 14 September 2014
      Source:The Lancet
      Author(s): Maria G Guzman , Eva Harris
      Dengue viruses have spread rapidly within countries and across regions in the past few decades, resulting in an increased frequency of epidemics and severe dengue disease, hyperendemicity of multiple dengue virus serotypes in many tropical countries, and autochthonous transmission in Europe and the USA. Today, dengue is regarded as the most prevalent and rapidly spreading mosquito-borne viral disease of human beings. Importantly, the past decade has also seen an upsurge in research on dengue virology, pathogenesis, and immunology and in development of antivirals, vaccines, and new vector-control strategies that can positively impact dengue control and prevention.


      PubDate: 2014-09-17T15:46:30Z
       
  • Global, regional, and national levels and causes of maternal mortality
           during 1990–2013: a systematic analysis for the Global Burden of
           Disease Study 2013
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Nicholas J Kassebaum , Amelia Bertozzi-Villa , Megan S Coggeshall , Katya A Shackelford , Caitlyn Steiner , Kyle R Heuton , Diego Gonzalez-Medina , Ryan Barber , Chantal Huynh , Daniel Dicker , Tara Templin , Timothy M Wolock , Ayse Abbasoglu Ozgoren , Foad Abd-Allah , Semaw Ferede Abera , Ibrahim Abubakar , Tom Achoki , Ademola Adelekan , Zanfina Ademi , Arsène Kouablan Adou , José C Adsuar , Emilie E Agardh , Dickens Akena , Deena Alasfoor , Zewdie Aderaw Alemu , Rafael Alfonso-Cristancho , Samia Alhabib , Raghib Ali , Mazin J Al Kahbouri , François Alla , Peter J Allen , Mohammad A AlMazroa , Ubai Alsharif , Elena Alvarez , Nelson Alvis-Guzmán , Adansi A Amankwaa , Azmeraw T Amare , Hassan Amini , Walid Ammar , Carl A T Antonio , Palwasha Anwari , Johan Ärnlöv , Valentina S Arsic Arsenijevic , Ali Artaman , Majed Masoud Asad , Rana J Asghar , Reza Assadi , Lydia S Atkins , Alaa Badawi , Kalpana Balakrishnan , Arindam Basu , Sanjay Basu , Justin Beardsley , Neeraj Bedi , Tolesa Bekele , Michelle L Bell , Eduardo Bernabe , Tariku J Beyene , Zulfiqar Bhutta , Aref Bin Abdulhak , Jed D Blore , Berrak Bora Basara , Dipan Bose , Nicholas Breitborde , Rosario Cárdenas , Carlos A Castañeda-Orjuela , Ruben Estanislao Castro , Ferrán Catalá-López , Alanur Cavlin , Jung-Chen Chang , Xuan Che , Costas A Christophi , Sumeet S Chugh , Massimo Cirillo , Samantha M Colquhoun , Leslie Trumbull Cooper , Cyrus Cooper , Iuri da Costa Leite , Lalit Dandona , Rakhi Dandona , Adrian Davis , Anand Dayama , Louisa Degenhardt , Diego De Leo , Borja del Pozo-Cruz , Kebede Deribe , Muluken Dessalegn , Gabrielle A deVeber , Samath D Dharmaratne , Uğur Dilmen , Eric L Ding , Rob E Dorrington , Tim R Driscoll , Sergei Petrovich Ermakov , Alireza Esteghamati , Emerito Jose A Faraon , Farshad Farzadfar , Manuela Mendonca Felicio , Seyed-Mohammad Fereshtehnejad , Graça Maria Ferreira de Lima , Mohammad H Forouzanfar , Elisabeth B França , Lynne Gaffikin , Ketevan Gambashidze , Fortuné Gbètoho Gankpé , Ana C Garcia , Johanna M Geleijnse , Katherine B Gibney , Maurice Giroud , Elizabeth L Glaser , Ketevan Goginashvili , Philimon Gona , Dinorah González-Castell , Atsushi Goto , Hebe N Gouda , Harish Chander Gugnani , Rahul Gupta , Rajeev Gupta , Nima Hafezi-Nejad , Randah Ribhi Hamadeh , Mouhanad Hammami , Graeme J Hankey , Hilda L Harb , Rasmus Havmoeller , Simon I Hay , Ileana B Heredia Pi , Hans W Hoek , H Dean Hosgood , Damian G Hoy , Abdullatif Husseini , Bulat T Idrisov , Kaire Innos , Manami Inoue , Kathryn H Jacobsen , Eiman Jahangir , Sun Ha Jee , Paul N Jensen , Vivekanand Jha , Guohong Jiang , Jost B Jonas , Knud Juel , Edmond Kato Kabagambe , Haidong Kan , Nadim E Karam , André Karch , Corine Kakizi Karema , Anil Kaul , Norito Kawakami , Konstantin Kazanjan , Dhruv S Kazi , Andrew H Kemp , Andre Pascal Kengne , Maia Kereselidze , Yousef Saleh Khader , Shams Eldin Ali Hassan Khalifa , Ejaz Ahmed Khan , Young-Ho Khang , Luke Knibbs , Yoshihiro Kokubo , Soewarta Kosen , Barthelemy Kuate Defo , Chanda Kulkarni , Veena S Kulkarni , G Anil Kumar , Kaushalendra Kumar , Ravi B Kumar , Gene Kwan , Taavi Lai , Ratilal Lalloo , Hilton Lam , Van C Lansingh , Anders Larsson , Jong-Tae Lee , James Leigh , Mall Leinsalu , Ricky Leung , Xiaohong Li , Yichong Li , Yongmei Li , Juan Liang , Xiaofeng Liang , Stephen S Lim , Hsien-Ho Lin , Steven E Lipshultz , Shiwei Liu , Yang Liu , Belinda K Lloyd , Stephanie J London , Paulo A Lotufo , Jixiang Ma , Stefan Ma , Vasco Manuel Pedro Machado , Nana Kwaku Mainoo , Marek Majdan , Christopher Chabila Mapoma , Wagner Marcenes , Melvin Barrientos Marzan , Amanda J Mason-Jones , Man Mohan Mehndiratta , Fabiola Mejia-Rodriguez , Ziad A Memish , Walter Mendoza , Ted R Miller , Edward J Mills , Ali H Mokdad , Glen Liddell Mola , Lorenzo Monasta , Jonathan de la Cruz Monis , Julio Cesar Montañez Hernandez , Ami R Moore , Maziar Moradi-Lakeh , Rintaro Mori , Ulrich O Mueller , Mitsuru Mukaigawara , Aliya Naheed , Kovin S Naidoo , Devina Nand , Vinay Nangia , Denis Nash , Chakib Nejjari , Robert G Nelson , Sudan Prasad Neupane , Charles R Newton , Marie Ng , Mark J Nieuwenhuijsen , Muhammad Imran Nisar , Sandra Nolte , Ole F Norheim , Luke Nyakarahuka , In-Hwan Oh , Takayoshi Ohkubo , Bolajoko O Olusanya , Saad B Omer , John Nelson Opio , Orish Ebere Orisakwe , Jeyaraj D Pandian , Christina Papachristou , Jae-Hyun Park , Angel J Paternina Caicedo , Scott B Patten , Vinod K Paul , Boris Igor Pavlin , Neil Pearce , David M Pereira , Konrad Pesudovs , Max Petzold , Dan Poenaru , Guilherme V Polanczyk , Suzanne Polinder , Dan Pope , Farshad Pourmalek , Dima Qato , D Alex Quistberg , Anwar Rafay , Kazem Rahimi , Vafa Rahimi-Movaghar , Sajjad ur Rahman , Murugesan Raju , Saleem M Rana , Amany Refaat , Luca Ronfani , Nobhojit Roy , Tania Georgina Sánchez Pimienta , Mohammad Ali Sahraian , Joshua A Salomon , Uchechukwu Sampson , Itamar S Santos , Monika Sawhney , Felix Sayinzoga , Ione J C Schneider , Austin Schumacher , David C Schwebel , Soraya Seedat , Sadaf G Sepanlou , Edson E Servan-Mori , Marina Shakh-Nazarova , Sara Sheikhbahaei , Kenji Shibuya , Hwashin Hyun Shin , Ivy Shiue , Inga Dora Sigfusdottir , Donald H Silberberg , Andrea P Silva , Jasvinder A Singh , Vegard Skirbekk , Karen Sliwa , Sergey S Soshnikov , Luciano A Sposato , Chandrashekhar T Sreeramareddy , Konstantinos Stroumpoulis , Lela Sturua , Bryan L Sykes , Karen M Tabb , Roberto Tchio Talongwa , ...
      PubDate: 2014-09-12T15:42:18Z
       
  • Global, regional, and national levels of neonatal, infant, and under-5
           mortality during 1990–2013: a systematic analysis for the Global
           Burden of Disease Study 2013
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Haidong Wang , Chelsea A Liddell , Matthew M Coates , Meghan D Mooney , Carly E Levitz , Austin E Schumacher , Henry Apfel , Marissa Iannarone , Bryan Phillips , Katherine T Lofgren , Logan Sandar , Rob E Dorrington , Ivo Rakovac , Troy A Jacobs , Xiaofeng Liang , Maigeng Zhou , Jun Zhu , Gonghuan Yang , Yanping Wang , Shiwei Liu , Yichong Li , Ayse Abbasoglu Ozgoren , Semaw Ferede Abera , Ibrahim Abubakar , Tom Achoki , Ademola Adelekan , Zanfina Ademi , Zewdie Aderaw Alemu , Peter J Allen , Mohammad AbdulAziz AlMazroa , Elena Alvarez , Adansi A Amankwaa , Azmeraw T Amare , Walid Ammar , Palwasha Anwari , Solveig Argeseanu Cunningham , Majed Masoud Asad , Reza Assadi , Amitava Banerjee , Sanjay Basu , Neeraj Bedi , Tolesa Bekele , Michelle L Bell , Zulfiqar Bhutta , Jed D Blore , Berrak Bora Basara , Soufiane Boufous , Nicholas Breitborde , Nigel G Bruce , Linh Ngoc Bui , Jonathan R Carapetis , Rosario Cárdenas , David O Carpenter , Valeria Caso , Ruben Estanislao Castro , Ferrán Catalá-Lopéz , Alanur Cavlin , Xuan Che , Peggy Pei-Chia Chiang , Rajiv Chowdhury , Costas A Christophi , Ting-Wu Chuang , Massimo Cirillo , Iuri da Costa Leite , Karen J Courville , Lalit Dandona , Rakhi Dandona , Adrian Davis , Anand Dayama , Kebede Deribe , Samath D Dharmaratne , Mukesh K Dherani , Uğur Dilmen , Eric L Ding , Karen M Edmond , Sergei Petrovich Ermakov , Farshad Farzadfar , Seyed-Mohammad Fereshtehnejad , Daniel Obadare Fijabi , Nataliya Foigt , Mohammad H Forouzanfar , Ana C Garcia , Johanna M Geleijnse , Bradford D Gessner , Ketevan Goginashvili , Philimon Gona , Atsushi Goto , Hebe N Gouda , Mark A Green , Karen Fern Greenwell , Harish Chander Gugnani , Rahul Gupta , Randah Ribhi Hamadeh , Mouhanad Hammami , Hilda L Harb , Simon Hay , Mohammad T Hedayati , H Dean Hosgood , Damian G Hoy , Bulat T Idrisov , Farhad Islami , Samaya Ismayilova , Vivekanand Jha , Guohong Jiang , Jost B Jonas , Knud Juel , Edmond Kato Kabagambe , Dhruv S Kazi , Andre Pascal Kengne , Maia Kereselidze , Yousef Saleh Khader , Shams Eldin Ali Hassan Khalifa , Young-Ho Khang , Daniel Kim , Yohannes Kinfu , Jonas M Kinge , Yoshihiro Kokubo , Soewarta Kosen , Barthelemy Kuate Defo , G Anil Kumar , Kaushalendra Kumar , Ravi B Kumar , Taavi Lai , Qing Lan , Anders Larsson , Jong-Tae Lee , Mall Leinsalu , Stephen S Lim , Steven E Lipshultz , Giancarlo Logroscino , Paulo A Lotufo , Raimundas Lunevicius , Ronan Anthony Lyons , Stefan Ma , Abbas Ali Mahdi , Melvin Barrientos Marzan , Mohammad Taufiq Mashal , Tasara T Mazorodze , John J McGrath , Ziad A Memish , Walter Mendoza , George A Mensah , Atte Meretoja , Ted R Miller , Edward J Mills , Karzan Abdulmuhsin Mohammad , Ali H Mokdad , Lorenzo Monasta , Marcella Montico , Ami R Moore , Joanna Moschandreas , William T Msemburi , Ulrich O Mueller , Magdalena M Muszynska , Mohsen Naghavi , Kovin S Naidoo , KM Venkat Narayan , Chakib Nejjari , Marie Ng , Jean de Dieu Ngirabega , Mark J Nieuwenhuijsen , Luke Nyakarahuka , Takayoshi Ohkubo , Saad B Omer , Angel J Paternina Caicedo , Victoria Pillay-van Wyk , Dan Pope , Farshad Pourmalek , Dorairaj Prabhakaran , Sajjad UR Rahman , Saleem M Rana , Robert Quentin Reilly , David Rojas-Rueda , Luca Ronfani , Lesley Rushton , Mohammad Yahya Saeedi , Joshua A Salomon , Uchechukwu Sampson , Itamar S Santos , Monika Sawhney , Jürgen C Schmidt , Marina Shakh-Nazarova , Jun She , Sara Sheikhbahaei , Kenji Shibuya , Hwashin Hyun Shin , Kawkab Shishani , Ivy Shiue , Inga Dora Sigfusdottir , Jasvinder A Singh , Vegard Skirbekk , Karen Sliwa , Sergey S Soshnikov , Luciano A Sposato , Vasiliki Kalliopi Stathopoulou , Konstantinos Stroumpoulis , Karen M Tabb , Roberto Tchio Talongwa , Carolina Maria Teixeira , Abdullah Sulieman Terkawi , Alan J Thomson , Andrew L Thorne-Lyman , Hideaki Toyoshima , Zacharie Tsala Dimbuene , Parfait Uwaliraye , Selen Begüm Uzun , Tommi J Vasankari , Ana Maria Nogales Vasconcelos , Vasiliy Victorovich Vlassov , Stein Emil Vollset , Stephen Waller , Xia Wan , Scott Weichenthal , Elisabete Weiderpass , Robert G Weintraub , Ronny Westerman , James D Wilkinson , Hywel C Williams , Yang C Yang , Gokalp Kadri Yentur , Paul Yip , Naohiro Yonemoto , Mustafa Younis , Chuanhua Yu , Kim Yun Jin , Maysaa El Sayed Zaki , Shankuan Zhu , Theo Vos , Alan D Lopez , Christopher J L Murray
      Background Remarkable financial and political efforts have been focused on the reduction of child mortality during the past few decades. Timely measurements of levels and trends in under-5 mortality are important to assess progress towards the Millennium Development Goal 4 (MDG 4) target of reduction of child mortality by two thirds from 1990 to 2015, and to identify models of success. Methods We generated updated estimates of child mortality in early neonatal (age 0–6 days), late neonatal (7–28 days), postneonatal (29–364 days), childhood (1–...
      PubDate: 2014-09-12T15:42:18Z
       
  • Department of Error
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947




      PubDate: 2014-09-12T15:42:18Z
       
  • Department of Error
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947




      PubDate: 2014-09-12T15:42:18Z
       
  • Privatisation of the Scottish NHS: TTIP and independence
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Mike Lean , Graham Watt , Hugh Bishop , Anne Mullin , Kenneth Barker



      PubDate: 2014-09-12T15:42:18Z
       
  • Global, regional, and national incidence and mortality for HIV,
           tuberculosis, and malaria during 1990–2013: a systematic analysis
           for the Global Burden of Disease Study 2013
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Christopher J L Murray , Katrina F Ortblad , Caterina Guinovart , Stephen S Lim , Timothy M Wolock , D Allen Roberts , Emily A Dansereau , Nicholas Graetz , Ryan M Barber , Jonathan C Brown , Haidong Wang , Herbert C Duber , Mohsen Naghavi , Daniel Dicker , Lalit Dandona , Joshua A Salomon , Kyle R Heuton , Kyle Foreman , David E Phillips , Thomas D Fleming , Abraham D Flaxman , Bryan K Phillips , Elizabeth K Johnson , Megan S Coggeshall , Foad Abd-Allah , Semaw Ferede Abera , Jerry P Abraham , Ibrahim Abubakar , Laith J Abu-Raddad , Niveen Me Abu-Rmeileh , Tom Achoki , Austine Olufemi Adeyemo , Arsène Kouablan Adou , José C Adsuar , Emilie Elisabet Agardh , Dickens Akena , Mazin J Al Kahbouri , Deena Alasfoor , Mohammed I Albittar , Gabriel Alcalá-Cerra , Miguel Angel Alegretti , Zewdie Aderaw Alemu , Rafael Alfonso-Cristancho , Samia Alhabib , Raghib Ali , Francois Alla , Peter J Allen , Ubai Alsharif , Elena Alvarez , Nelson Alvis-Guzman , Adansi A Amankwaa , Azmeraw T Amare , Hassan Amini , Walid Ammar , Benjamin O Anderson , Carl Abelardo T Antonio , Palwasha Anwari , Johan Ärnlöv , Valentina S Arsic Arsenijevic , Ali Artaman , Rana J Asghar , Reza Assadi , Lydia S Atkins , Alaa Badawi , Kalpana Balakrishnan , Amitava Banerjee , Sanjay Basu , Justin Beardsley , Tolesa Bekele , Michelle L Bell , Eduardo Bernabe , Tariku Jibat Beyene , Neeraj Bhala , Ashish Bhalla , Zulfiqar A Bhutta , Aref Bin Abdulhak , Agnes Binagwaho , Jed D Blore , Berrak Bora Basara , Dipan Bose , Michael Brainin , Nicholas Breitborde , Carlos A Castañeda-Orjuela , Ferrán Catalá-López , Vineet K Chadha , Jung-Chen Chang , Peggy Pei-Chia Chiang , Ting-Wu Chuang , Mercedes Colomar , Leslie Trumbull Cooper , Cyrus Cooper , Karen J Courville , Benjamin C Cowie , Michael H Criqui , Rakhi Dandona , Anand Dayama , Diego De Leo , Louisa Degenhardt , Borja Del Pozo-Cruz , Kebede Deribe , Don C Des Jarlais , Muluken Dessalegn , Samath D Dharmaratne , Uğur Dilmen , Eric L Ding , Tim R Driscoll , Adnan M Durrani , Richard G Ellenbogen , Sergey Petrovich Ermakov , Alireza Esteghamati , Emerito Jose A Faraon , Farshad Farzadfar , Seyed-Mohammad Fereshtehnejad , Daniel Obadare Fijabi , Mohammad H Forouzanfar , Urbano Fra.Paleo , Lynne Gaffikin , Amiran Gamkrelidze , Fortuné Gbètoho Gankpé , Johanna M Geleijnse , Bradford D Gessner , Katherine B Gibney , Ibrahim Abdelmageem Mohamed Ginawi , Elizabeth L Glaser , Philimon Gona , Atsushi Goto , Hebe N Gouda , Harish Chander Gugnani , Rajeev Gupta , Rahul Gupta , Nima Hafezi-Nejad , Randah Ribhi Hamadeh , Mouhanad Hammami , Graeme J Hankey , Hilda L Harb , Josep Maria Haro , Rasmus Havmoeller , Simon I Hay , Mohammad T Hedayati , Ileana B Heredia Pi , Hans W Hoek , John C Hornberger , H Dean Hosgood , Peter J Hotez , Damian G Hoy , John J Huang , Kim M Iburg , Bulat T Idrisov , Kaire Innos , Kathryn H Jacobsen , Panniyammakal Jeemon , Paul N Jensen , Vivekanand Jha , Guohong Jiang , Jost B Jonas , Knud Juel , Haidong Kan , Ida Kankindi , Nadim E Karam , André Karch , Corine Kakizi Karema , Anil Kaul , Norito Kawakami , Dhruv S Kazi , Andrew H Kemp , Andre Pascal Kengne , Andre Keren , Maia Kereselidze , Yousef Saleh Khader , Shams Eldin Ali Hassan Khalifa , Ejaz Ahmed Khan , Young-Ho Khang , Irma Khonelidze , Yohannes Kinfu , Jonas M Kinge , Luke Knibbs , Yoshihiro Kokubo , S Kosen , Barthelemy Kuate Defo , Veena S Kulkarni , Chanda Kulkarni , Kaushalendra Kumar , Ravi B Kumar , G Anil Kumar , Gene F Kwan , Taavi Lai , Arjun Lakshmana Balaji , Hilton Lam , Qing Lan , Van C Lansingh , Heidi J Larson , Anders Larsson , Jong-Tae Lee , James Leigh , Mall Leinsalu , Ricky Leung , Yichong Li , Yongmei Li , Graça Maria Ferreira De Lima , Hsien-Ho Lin , Steven E Lipshultz , Shiwei Liu , Yang Liu , Belinda K Lloyd , Paulo A Lotufo , Vasco Manuel Pedro Machado , Jennifer H Maclachlan , Carlos Magis-Rodriguez , Marek Majdan , Christopher Chabila Mapoma , Wagner Marcenes , Melvin Barrientos Marzan , Joseph R Masci , Mohammad Taufiq Mashal , Amanda J Mason-Jones , Bongani M Mayosi , Tasara T Mazorodze , Abigail Cecilia Mckay , Peter A Meaney , Man Mohan Mehndiratta , Fabiola Mejia-Rodriguez , Yohannes Adama Melaku , Ziad A Memish , Walter Mendoza , Ted R Miller , Edward J Mills , Karzan Abdulmuhsin Mohammad , Ali H Mokdad , Glen Liddell Mola , Lorenzo Monasta , Marcella Montico , Ami R Moore , Rintaro Mori , Wilkister Nyaora Moturi , Mitsuru Mukaigawara , Kinnari S Murthy , Aliya Naheed , Kovin S Naidoo , Luigi Naldi , Vinay Nangia , K M Venkat Narayan , Denis Nash , Chakib Nejjari , Robert G Nelson , Sudan Prasad Neupane , Charles R Newton , Marie Ng , Muhammad Imran Nisar , Sandra Nolte , Ole F Norheim , Vincent Nowaseb , Luke Nyakarahuka , In-Hwan Oh , Takayoshi Ohkubo , Bolajoko O Olusanya , Saad B Omer , John Nelson Opio , Orish Ebere Orisakwe , Jeyaraj D Pandian , Christina Papachristou , Angel J Paternina Caicedo , Scott B Patten , Vinod K Paul , Boris Igor Pavlin , Neil Pearce , David M Pereira , Aslam Pervaiz , Konrad Pesudovs , Max Petzold , Farshad Pourmalek , Dima Qato , Amado D Quezada , D Alex Quistberg , Anwar Rafay , Kazem Rahimi , Vafa Rahimi-Movaghar , Sajjad Ur Rahman , Murugesan Raju , Saleem M Rana , Homie Razavi , Robert Quentin Reilly , Giuseppe Remuzzi , Jan Hendrik Richardus , Luca Ronfani , Nobhojit Roy , Nsanzimana Sabin , Mohammad Yahya Saeedi , Mohammad Ali Sahraian , Genesis May J Samonte , Monika Sawhney , Ione J C Schneider , David C Schwebel , Soraya Seedat , S...
      PubDate: 2014-09-12T15:42:18Z
       
  • Violence against doctors in India
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Himmatrao Saluba Bawaskar



      PubDate: 2014-09-12T15:42:18Z
       
  • Publication pressure on Chinese doctors—another view
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Shanquan Chen , Yao Pan , Qiang Yao , Lan Yao , Zhiyong Liu , Li Xiang



      PubDate: 2014-09-12T15:42:18Z
       
  • Department of Error
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947




      PubDate: 2014-09-12T15:42:18Z
       
  • The US Centers for Disease Control: a crucial actor in global health
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Johanna Hanefeld



      PubDate: 2014-09-12T15:42:18Z
       
  • Health of Americans
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Derek Yach



      PubDate: 2014-09-12T15:42:18Z
       
  • Electronic health records in the UK and USA
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Owen A Johnson , Hamish S F Fraser , Jeremy C Wyatt , John D Walley



      PubDate: 2014-09-12T15:42:18Z
       
  • Violence against doctors in Iraq
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Sadeer Al-Kindi



      PubDate: 2014-09-12T15:42:18Z
       
  • Tackling violence against health-care workers in Spain
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Manuel María Ortega Marlasca



      PubDate: 2014-09-12T15:42:18Z
       
  • Simvastatin in patients with progressive multiple sclerosis
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Gavin Giovannoni , David Baker , Klaus Schmierer



      PubDate: 2014-09-12T15:42:18Z
       
  • Simvastatin in patients with progressive multiple sclerosis–Authors'
           reply
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Jeremy Chataway



      PubDate: 2014-09-12T15:42:18Z
       
  • Can dementia be lessened by statins'
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Lionel H Opie



      PubDate: 2014-09-12T15:42:18Z
       
  • Judy Wasserheit: positively global
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Geoff Watts



      PubDate: 2014-09-12T15:42:18Z
       
  • “Hello it's me…why aren't you there'”
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Bob Heath



      PubDate: 2014-09-12T15:42:18Z
       
  • Helen Bamber
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Jeremy Laurance



      PubDate: 2014-09-12T15:42:18Z
       
  • Simvastatin in patients with progressive multiple sclerosis
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Johann Auer , Robert Berent



      PubDate: 2014-09-12T15:42:18Z
       
  • Offline: The case for a medical school revolution
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Richard Horton



      PubDate: 2014-09-12T15:42:18Z
       
  • Lasker Foundation announces 2014 award winners
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Brian Owens



      PubDate: 2014-09-12T15:42:18Z
       
  • Iraq: staff and medicine shortages are major challenges
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Sophie Cousins



      PubDate: 2014-09-12T15:42:18Z
       
  • Global health justice Lawrence OGostinGlobal Health Law2014Harvard
           University Press9780674728844560US$55·00.
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Sofia Gruskin



      PubDate: 2014-09-12T15:42:18Z
       
  • Time for a revolution in reporting of global health data
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Rifat Atun



      PubDate: 2014-09-12T15:42:18Z
       
  • Emergency preservation and resuscitation: a Lazarus trial'
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): William Squiers



      PubDate: 2014-09-12T15:42:18Z
       
  • MDG 6 and beyond: from halting and reversing AIDS to ending the epidemic
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Michel Sidibé , Mark Dybul , Deborah Birx



      PubDate: 2014-09-12T15:42:18Z
       
  • Scotland: towards a healthy and interdependent future
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): The Lancet



      PubDate: 2014-09-12T15:42:18Z
       
  • The child survival revolution: what next'
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Joy E Lawn



      PubDate: 2014-09-12T15:42:18Z
       
  • Counting what counts for maternal mortality
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): Wendy J Graham , Sophie Witter



      PubDate: 2014-09-12T15:42:18Z
       
  • The silver bullet of resilience
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): The Lancet



      PubDate: 2014-09-12T15:42:18Z
       
  • Organ distribution by redesign
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947
      Author(s): The Lancet



      PubDate: 2014-09-12T15:42:18Z
       
  • September 13–19, 2014
    • Abstract: Publication date: 13–19 September 2014
      Source:The Lancet, Volume 384, Issue 9947




      PubDate: 2014-09-12T15:42:18Z
       
  • Ebola control measures and inadequate responses
    • Abstract: Publication date: Available online 9 September 2014
      Source:The Lancet
      Author(s): Timothy W Ryschon



      PubDate: 2014-09-12T15:42:18Z
       
  • Ebola: a failure of international collective action
    • Abstract: Publication date: Available online 10 September 2014
      Source:The Lancet
      Author(s): Mit Philips , Áine Markham



      PubDate: 2014-09-12T15:42:18Z
       
  • Compassionate use of experimental drugs in the Ebola outbreak
    • Abstract: Publication date: Available online 11 September 2014
      Source:The Lancet
      Author(s): Morenike Folayan , Brandon Brown , Aminu Yakubu , Kristin Peterson , Bridget Haire



      PubDate: 2014-09-12T15:42:18Z
       
  • Glucagon-like peptide-1 receptor agonist and basal insulin combination
           treatment for the management of type 2 diabetes: a systematic review and
           meta-analysis
    • Abstract: Publication date: Available online 11 September 2014
      Source:The Lancet
      Author(s): Conrad Eng , Caroline K Kramer , Bernard Zinman , Ravi Retnakaran
      Background Combination treatment with a glucagon-like peptide-1 (GLP-1) agonist and basal insulin has been proposed as a treatment strategy for type 2 diabetes that could provide robust glucose-lowering capability with low risk of hypoglycaemia or weight gain. We thus did a systematic review and meta-analysis of randomised controlled trials to assess the effect of this combination treatment on glycaemic control, hypoglycaemia, and weight gain in patients with type 2 diabetes. Methods We systematically searched PubMed, Embase, Cochrane, Web of Knowledge, FDA.gov, and ClinicalTrials.gov for randomised controlled trials (published between Jan 1, 1950, and July 29, 2014; no language restrictions) comparing GLP-1 agonist and basal insulin combination treatment to other anti-diabetic treatments. Our main endpoints were glycaemic control, hypoglycaemia, and change in weight. We assessed pooled data by use of a random-effects model. Findings Of 2905 identified studies, 15 were eligible and were included in our analysis (N=4348 participants). Compared with other anti-diabetic treatments, GLP-1 agonist and basal insulin combination treatment yielded an improved mean reduction in glycated haemoglobin (HbA1c) of −0·44% (95% CI −0·60 to −0·29), an improved likelihood of achieving the target HbA1c of 7·0% or lower (relative risk [RR] 1·92; 95% CI 1·43 to 2·56), no increased relative risk of hypoglycaemia (0·99; 0·76 to 1·29), and a mean reduction in weight of −3·22 kg (−4·90 to −1·54). Furthermore, compared with basal-bolus insulin regimens, the combination treatment yielded a mean reduction in HbA1c of −0·1% (−0·17 to −0·02), with lower relative risk of hypoglycaemia (0·67, 0·56 to 0·80), and reduction in mean weight (−5·66 kg; −9·8 to −1·51). Interpretation GLP-1 agonist and basal insulin combination treatment can enable achievement of the ideal trifecta in diabetic treatment: robust glycaemic control with no increased hypoglycaemia or weight gain. This combination is thus a potential therapeutic strategy that could improve the management of patients with type 2 diabetes. Funding None.


      PubDate: 2014-09-12T15:42:18Z
       
  • GLP-1 receptor agonists and basal insulin in type 2 diabetes
    • Abstract: Publication date: Available online 11 September 2014
      Source:The Lancet
      Author(s): Laura A Young , John B Buse



      PubDate: 2014-09-12T15:42:18Z
       
  • Taking a religious perspective to contain Ebola
    • Abstract: Publication date: Available online 3 September 2014
      Source:The Lancet
      Author(s): Sulaiman M Bah , Abdullah S Aljoudi



      PubDate: 2014-09-04T15:34:10Z
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014